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1128This manuscript describes the coronary artery patterns in 64
consecutive patients undergoing repair of PA/VSD/MAPCA.
Twenty-seven percent of the patients had an anomalous origin and
course of their coronary arteries. The most frequently observed
anomalous course was a LAD originating from the right coronary
and accounted for 15% of all anomalous patterns.
This prevalence of coronary arterial anomalies in PA/VSD/
MAPCA is at the high end of the spectrum compared with other
forms of conotruncal defects.
There was a 91% correlation between the coronary artery
patterns identiﬁed at surgery and the ﬁndings described by cardiac
catheterization. The 9% of patients who were not correctly iden-
tiﬁed at catheterization were all false negatives. The speciﬁcity of
cardiac catheterization was 100% and the sensitivity was 65%. Five
of the 6 false negatives had 2 separate coronary ostia, emphasizing
the need to exclude all 4 anomalous coronary patterns.
Recognition of coronary artery anomalies is important in PA/VSD/
MAPCA due to the need for placement of a conduit from the right
ventricle to the reconstructed pulmonary arteries. The surface anatomy
of the coronary system is discernible at the time of the ﬁrst surgical
procedure, and this is why this is a requirement for inclusion in this
study. The ability to see the coronary arterial pattern at ﬁrst surgery
allows safe placement of the proximal end of the conduit regardless of
the presence or absence of anomalous coronaries. The surface anatomy
is obscured in subsequent re-operations, and during these subsequent
conduit changes, injury to coronary arteries can occur. In view of the
relatively high prevalence of anomalous coronaries in PA/VSD/
MAPCA, it is imperative to identify the coronary artery pattern prior to
contemplating re-operations for conduit replacement.
In summary, this study has documented a 27% incidence of
anomalous coronary arteries in patients with PA/VSD/MAPCA.
This information is clinically important to avoid coronary injuries
during conduit re-operations.
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1397–402.Letters to the EditorAll Vasodilators Are Not EqualWe read with interest the paper published by Naya et al. (1), in
which they suggest that global coronary ﬂow reserve (CFR), and
not coronary artery calcium, as assessed by positron emission
tomographic (PET) myocardial perfusion imaging (MPI), provides
signiﬁcant incremental improved risk stratiﬁcation over clinical risk
scores for prediction of major adverse cardiac events (1). However,
we feel the results should be interpreted with caution for the
following reasons.
This large study (n¼ 901) permitted the use of 4 different types of
vasodilators to assess CFR: dipyridamole (52% of patients), rega-
denoson (38%), adenosine (5%), and dobutamine (5%). The inves-
tigators assumed that each pharmacological agent would produce an
equivalent vasodilator effect, and therefore, allow collective
comparison of CFR with outcome variables. However, this
assumption is unproven and unlikely to be correct given their
different modes of action. As such, this could have a profound effect
on the study endpoints. Previous comparative studies that have
involved small numbers of patients have demonstrated that these
pharmacological agents produce signiﬁcantly different magnitudes
of hemodynamic and vasodilator effects. Importantly, where
differences have not been shown, this does not mean they do not
exist, and may be due to the limited numbers of patients studied.
Vasu et al. (2) used stress cardiac magnetic resonance imaging
(MRI) in 40 patients and showed that regadenoson had a 20%
signiﬁcantly greater vasodilator effect than dipyridamole on myo-
cardial blood ﬂow reserve. In 20 healthy volunteers, dobutamine-
atropine infusion caused a 40% greater increase in peak myocardial
blood ﬂow as measured by PETMPI in comparison to dipyridamole
(3). In a separate study, adenosine was shown to produce a signiﬁ-
cantly greater decrease in mean arterial blood pressure than dipyr-
idamole, and althoughmyocardial bloodﬂow reservewas numerically
greater with adenosine, it did not reach statistical signiﬁcance (4).
This study involved just 15 patients.
The investigators also attempted to exclude patients with
obstructive coronary artery disease from the study on the basis of
an abnormal PET MPI. As a result, almost a quarter of the 1,240
patients screened were rejected. Unfortunately, an inherent
methodological problem, known as incorporation bias, arises
when the same technique is used both as a gatekeeper for
“abnormal patients” and also acts as the diagnostic test. This
problem is further compounded when no criteria are given as to
how an “abnormal PET MPI” was deﬁned. For example, readers
would wish to know whether all 1,240 PET MPI scans had ﬂows
quantitatively assessed. In which case, what cutoff values for
blood ﬂow were used to deﬁne obstructive disease? Clearly,
inadvertent exclusion of scans presumed to be abnormal due to
obstructive coronary artery disease, but which were due to
microvascular dysfunction, could signiﬁcantly affect the outcome
of the study.
We look forward to the authors’ reply.
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18:485–91.ReplyAll Vasodilators Are Not Equal
We appreciate the commentary by Ms. Nel and Greaves regarding
our study (1). Previous studies have demonstrated that dipyr-
idamole, regadenoson, and adenosine all achieve maximal coronary
hyperemic ﬂow via endothelial-independent vasodilation of the
microvasculature (2–4). Although dobutamine stress has a different
mechanism of action, the resulting hyperemia is similar in magni-
tude to adenosine (5). More important, in both the larger cohort
from which this study was derived (6) and in other large cohorts (7),
the stressor used was not informative to the multivariable model
for predicting cardiac events. Accordingly, we do not believe that
the use of multiple stress agents is likely to have resulted in a type 1
error or a false-positive association between CFR and outcomes.
In response to concerns raised by Nel and Greaves regarding
incorporation bias, this problem occurs in diagnostic studies in which
the test being evaluated is available to referring clinicians, and thus,
may inﬂuence the diagnostic endpoint. In our study of prognosis,
CFR was not available to referring clinicians, and consequently,
could not have inﬂuenced clinical decision making. Furthermore, the
clinical endpoints were adjudicated blinded to CFR values. Finally,
for inclusion in this study, normal PET myocardial perfusion
imaging was deﬁned not on the basis of CFR, but rather on
semiquantitative interpretation of myocardial perfusion scans.
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Pulmonary Vein Isolation With
Versus Without Concomitant
Renal Artery Denervation in
Patients With Refractory
Symptomatic Atrial Fibrillation
and Resistant Hypertension
With the advent of renal artery denervation, numerous publications
have been forthcoming. Previously, we petitioned the Journal as well
as other publications about the lack of citation of our earlier studies
(1–6) using intravascular electrode catheters to ablate autonomic
nerves on the outside of blood vessels. We can appreciate the
reluctance of the Journal to include these citations at that time based
on the difference between the intravascular ablation of nerves in the
renal arteries affecting blood pressure (7,8) rather than intravascular
ablation of nerves outside of blood vessels affecting heart rate and
cardiac arrhythmias (9). However, recent reports have documented
the consistent and independent effects of renal sympathetic dener-
vation (RSD) on heart rate reduction (10,11). More conclusive
evidence supporting our contention is based on the experimental
studies of Zhao et al. (12) and the recent clinical study by Pokushalov
et al. (13), which have shown that RSD can be used to reduce the
